NIBR-LTSi is a Selective LATS Kinase Inhibitor Activating YAP Signaling and Expanding Tissue Stem Cells in Vitro and in Vivo

Kenji Namoto, Clara Baader,Vanessa Orsini,Alexandro Landshammer,Eva Breuer, Kieu Trinh Dinh,Rosemarie Ungricht,Monika Pikiolek, Stephane Laurent,Bo Lu,Alexandra Aebi,Katharina Schoenberger Nberger,Eric Vangrevelinghe,Olivera Evrova,Tianliang Sun,Stefano Annunziato,Julie Lachal, Emily Redmond,Louis Wang,Kristie Wetzel,Paola Capodieci,Jonathan Turner,Gabi Schutzius, Vincent Unterreiner,Markus Trunzer, Nicole Buschmann,Dirk Behnke,Rainer Machauer,Clemens Scheufler,Christian N. Parker, Magali Ferro, Armelle Grevot, Armin Beyerbach,Wei-Yu Lu,Stuart J. Forbes, Jueurorgen Wagner,Tewis Bouwmeester, Jun Liu, Bindi Sohal, Sukhdeep Sahambi,Linda E. Greenbaum,Felix Lohmann,Philipp Hoppe,Feng Cong,Andreas W. Sailer,Heinz Ruffner,Ralf Glatthar,Bostjan Humar, Pierre-Alain Clavien,Michael T. Dill,Elizabeth George, Jueurorgen Maibaum,Prisca Liberali,Jan S. Tchorz

CELL STEM CELL（2024）

Cited 3|Views32

Key words

YAP/Hippo pathway,LATS kinase inhibitor,YAP agonist,drug development,tissue regeneration,liver regeneration,tissue stem cells,organoid expansion,wound healing,regenerative medicine

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined